Flu Watch in Taiwan: Taiwan’s CDC reported 138,654 flu-related outpatient and emergency visits last week, down 3.2% week-on-week, but with 87 new severe cases and 30 deaths; influenza A(H1N1) remains dominant, and the epidemic is expected to ease around mid-October though visits could still spike to 150,000–160,000. Obesity Drug Deal: Novo Nordisk will pay up to $2.6B to China’s Hengrui for rights to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist; the license excludes mainland China, Hong Kong, Macao and Taiwan, and could expand global metabolic-disease options. Taiwan in US Pharma Tariff Relief: The US Commerce Department listed Taiwan among 20 jurisdictions getting 0% duty on select speciality medicines (rare diseases, fertility, cell/gene therapies, ADCs, and related inputs) even as a broader 100% tariff regime expands. Heat Risk: Taiwan’s CWA issued late-September heat advisories for eight areas, urging hydration and reduced outdoor exertion due to “Autumn Tiger” conditions. Healthcare Business Tech: MIMS said it’s accelerating product innovation and international growth, rolling out AI-enabled clinical decision support platforms.